Media
-
The Australian reports the successful conclusion of Racura’s lead drug AML study
The Australian reports the conclusion of Racura’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by Professor Arnon Nagler. The results show that 40% of patients with highly advanced disease showing a response to bisantrene. Read the…
-
Racura Executive Director on Disrupt Radio
Racura Oncology Executive Director Dr Peter Smith joined Disrupt Radio to discuss building biotech businesses in Australia, what to look out for when investing in biotech businesses, and why Racura’s lead drug bisantrene is a unique asset carrying great clinical and commercial potential. You can listen to Dr Smith’s full interview via this link.
-
Proactive: Racura Oncology On Track For Clinical Trials Following ‘Excellent’ RC220 Bisantrene Safety And Toxicology Results
Racura CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene. Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It gives the new formulation of bisantrene IP and protection, moves the drug closer to human clinical trial, and marks a starting…
-
The Australian: Racura Moves Closer To Phase 1 Trial With Key CRO Appointment
The Australian reports that Racura Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients. Read the full article here.
-
Motley Fool: ASX Healthcare Stock Surges 11% On ‘Incredibly Valuable’ FDA News
The Motley Fool reports on the exciting news that Racura has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric acute myeloid leukemia. Read the full analysis here.
-
The Australian: Racura Oncology Stock Gains On US FDA Milestone
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Racura’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric AML may qualify Racura to be eligible for a Priority Review Voucher (PRV). Racura’s Executive Director, Dr Peter Smith, explains in…
-
Proactive: Racura Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment
Proactive reports that Racura has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Racura CEO Dr Daniel Tillett commented: “The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib,…
-
Proactive: Racura Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220
The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Racura CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene. Read the full report here.
-
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Racura Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability to deliver both anti-cancer and cardioprotection, and its current stage of clinical development. He also answers a range of questions from…
